Data de publicação: 12/04/2022 - 17:33
Released this Friday (April 4), the Fiocruz COVID-19 Observatory Report shows maintenance of the falling trend of COVID-19 incidence and mortality indicators. The document highlights that for the first time since May 2020, no Brazilian state has exceeded 0.3 deaths per 100,000 inhabitants. The researchers state that according to these new data it is possible to say that the third epidemic wave in Brazil, with a predominance of Omicron among the...
Notícias
Data de publicação: 08/04/2022 - 15:33
Last Tuesday (March 29), Fiocruz and Drugs for Neglected Diseases initiative (DNDi) signed a Memorandum of Understanding for dengue fever research and treatment. The occasion also sealed a Strategic Research Alliance between the two institutions and the joint submission of a project to the Finep Public Call for Neglected Diseases.
In addition to signing the Memorandum of Understanding for dengue fever, the occasion sealed a Strategic...
Notícias
Data de publicação: 30/03/2022 - 10:15
In a meeting promoted on March 28, by the Center for International Relations in Health (Cris/Fiocruz) and the Vice-Presidencies of Research and Biological Collections (VPPCB) and Education, Information and Communication (VPEIC), members of the Consulate General of the United States in Rio de Janeiro continued the partnership process initiated in 2021. The aim is to expand scientific cooperation between Fiocruz and American institutions....
Notícias
Data de publicação: 24/03/2022 - 15:43
At a meeting that took place last Friday (March 19), representatives of Fiocruz and of the Deutsche Forschungsgemeinschaft (DFG), a German non-profit organization that stimulates research, got together to strengthen bilateral cooperation between the institutions and to discuss possible foment partnerships. As a first step in this direction, a workshop was suggested to evaluate the opportunities, identifying possibilities among ongoing projects...
Notícias
Data de publicação: 23/03/2022 - 16:44
Unitaid, the global health agency connected to the WHO, will be financing the implementation of the project for Injectable Pre-Exposure Prophylaxy in Brazil, using long-acting Cabotegravir. With only six injections per year, the method has proven to be more effective than daily oral PrEP in terms of reducing the risk of infection by the virus. The project will be coordinated by the Evandro Chagas National Infectiology Institute (INI/Fiocruz) in...
Notícias
Data de publicação: 23/03/2022 - 16:42
A study by researchers of Fiocruz and of the University of Columbia has identified promising results in a combination of antiviral drugs for the treatment of COVID-19. Scientists showed that there is a synergy between the substances, inhibiting the enzymes that allow Sars-CoV-2 to multiply more effectively. Together, the drugs may reduce viral replication about ten times more than if taken separately.
The drugs studied are already...
Notícias
Data de publicação: 21/03/2022 - 17:54
The war in Ukraine has been thoroughly divulged, discussed, and explained on all social media platforms, in Brazil and abroad. Its geopolitical, economic, and social consequences have also been explored by specialists of all fields of knowledge and geographical position. However, there is one dimension that has been left out by this widely encompassing debate: the matter of health.
On the other hand, more attentive readers will certainly not...
Notícias
Data de publicação: 16/03/2022 - 11:20
Through the Institute of Drug Technology (Farmanguinhos) and French laboratory Servier, Fiocruz signed, last Thursday (March 10th), a Memorandum of Understanding for technical cooperation to develop new drugs against chronic diseases, from a new pharmaceutical platform. This is an innovative technology based on the prolonged release of the active ingredient in the body, resulting in efficacy, safety, and more compliance and practicality for...
Notícias
Data de publicação: 08/03/2022 - 15:43
Vaccination can protect the population against contamination, hospitalization, and death by COVID-19, even in socially vulnerable communities with high transmission rates. This is one of the main conclusions of a new paper of the "Vacina Maré" (vaccinate Maré, in english) research, which evaluates the effectiveness of the Fiocruz/AstraZeneca vaccine against getting sick with COVID-19, in Complexo da Maré, a complex...
Notícias
Data de publicação: 25/02/2022 - 15:01
In this role for less than five months, the new Ecuador ambassador in Brazil, Carlos Alberto Velástegui, visited Fiocruz last Friday (February 18) to strengthen the ties between his country and the Foundation. In the company of consul Marco Larrea, he was welcomed by Fiocruz president, Nísia Trindade Lima, and showed interest in defining areas for possible cooperation with Ecuador institutions and in getting to know more about the...
Notícias
Data de publicação: 22/02/2022 - 16:51
The Oswaldo Cruz Foundation (Fiocruz), through the Immunobiological Technology Institute (Biomanguinhos), provides the first doses of the COVID-19 vaccine (recombinant) produced with the national Active Pharmaceutical Ingredient (API). The first batch of national vaccines was released by the internal quality control of Bio-Manguinhos on 2/14.
“The release of the first 100% Brazilian COVID-19 vaccines, now available to the Ministry of...
Notícias
Data de publicação: 15/02/2022 - 10:42
In a geopolitical context marked by disputes and inequalities, there are many economic, social, and environmental challenges in the path of those aiming to reduce these inequalities and achieve better global health outcomes. Based on this point of view, issues such as multilateralism and a possible new world order were discussed last Thursday (February 10) during the first Advanced Seminar in Global Health and Health Diplomacy this year....
Notícias
Data de publicação: 09/02/2022 - 17:07
A study analyzed the geographic distribution and the incidence of co-infection with a human T-lymphotropic virus (HTLV) and a human immunodeficiency virus (HIV) in Bahia, which is an endemic state for both retroviruses. The research was carried out using all samples submitted to serological tests at the Central Public Health Laboratory of Bahia (Lacen-BA), from 2004 to 2013. The total was about 130,000 samples from 358 of the 417 municipalities...
Notícias
Data de publicação: 08/02/2022 - 16:21
As reported by the State Health Secretariats of Rio de Janeiro and Santa Catarina, Fiocruz has identified three cases of the BA.2 lineage of the Omicron variant, using genetic sequencing. Two of the cases occurred in Rio de Janeiro and the other in the southern state of Santa Catarina. The findings were confirmed by the Laboratory of Measles and Respiratory Viruses of the Oswaldo Cruz Institute (IOC/Fiocruz), a national reference center for...
Notícias
Data de publicação: 19/01/2022 - 17:49
We all had some degree of hope that the end of 2021 and the beginning of 2022 would bring us the much-awaited retraction of the pandemic. However, the emergence of the new Omicron variant dragged us away from the end of the tunnel we were longing for. Many countries, including some with powerful health systems, excellent living conditions, and high levels of vaccination, are hitting record numbers of contagions every day.
So far, the...
Notícias
Data de publicação: 19/01/2022 - 17:26
Science, technology and innovation to create resiliency, recover the planet from the impacts of COVID-19 and prepare it to face future health crises, including the ones resulting from environmental problems. This was the focus of the Global Sustainable Technology and Inovation Conference (G-Stic), an international reference in the debate that relates science, technology and innovation to the 2030 Agenda, which took place in Dubai from January...
Notícias
Data de publicação: 10/01/2022 - 14:43
This Friday (January 7), Fiocruz received assent from the National Agency of Sanitary Surveillance (Anvisa) for the alteration in the register of the COVID-19 vaccine (recombinant), which requested the addition of the Foundation as a producer of the Active Pharmaceutical Ingredient (API). After the transference of the AstraZeneca technology and with the approval of Anvisa, the Foundation is now the first institution in the country that is...
Notícias
Data de publicação: 04/01/2022 - 15:30
A study published on medRXiv, this Wednesday (December 29th), shows that the four vaccines applied in Brazil provide a high degree of additional protection against symptomatic infections and severe cases of COVID-19 in people who had already contracted Sars-CoV-2 previously. The study, led by Julio Croda and Manoel Barral-Neto, Fiocruz researchers, also reinforces the importance of a full vaccination scheme, even for those people.
Vaccine...
Notícias
Data de publicação: 03/01/2022 - 12:40
For three consecutive mornings in Brazil, or three nights on the other side of the world, in China, the CAS-Fiocruz webinar on Infectous Diseases brought together researchers from the Foundation and the Chinese Academy of Sciences to exchange information on topics such as COVID-19, vaccines, zika, dengue, and other diseases common to both sides of the globe. The webinar took place on December 14th, 15th, and 16th.
The event opening, on...
Notícias
Data de publicação: 23/12/2021 - 09:52
The ties between Fiocruz and the United States Consulate in Rio de Janeiro should become closer next year. On 12/16, the consul Jacqueline Ward and the president of Fiocruz, Nísia Trindade Lima, met at the Official Residence. On the agenda, scientific cooperation between Brazilian and American institutions, the XVI National Malaria Research Meeting and a parallel symposium organized by the Foundation and the National Institute of Allergy...
Notícias
Data de publicação: 17/12/2021 - 12:14
When the World Health Organization (WHO) decided to classify the Omicron strain of the new coronavirus as a variant of concern, it took into account the recommendations of a group of specialists. The so-called Technical Advisory Group on Sars-CoV-2 Evolution (TAG-VE) is a select group of scientists that includes a Brazilian virologist in its line-up: Brazilian researcher Marilda Siqueira, chief of the Laboratory of Measles and Respiratory...
Notícias
Data de publicação: 16/12/2021 - 09:23
The first edition of the bulletin on the COVID-19 vaccines' effectiveness in the Brazilian population, from Fiocruz's Vigivac project, was published on Thursday (12/9). The report, which presents analyses of the four vaccines administered in Brazil from January to October 2021, points out that all of them confer a great reduction in the risk of infection, hospitalizations, and death from COVID-19. Considering serious outcomes (...
Notícias
Data de publicação: 14/12/2021 - 17:24
In a pioneering initiative, the Foundation inaugurates this Monday (13/12), COVID-19 Biobank (BC19-Fiocruz). Located in Rio de Janeiro, at Expansão campus, BC19-Fiocruz will enable the design and conduct of research, technological development and clinical trials related to COVID-19, regardless of the geographic location of human biological material and viruses. With the capacity to store up to one and a half million samples of human and...
Notícias
Data de publicação: 14/12/2021 - 16:48
A research published today by The Lancet - one of the most prestigious scientific journals focused on the medical field in the world - brought together experts to explain how the economic downturn will affect for years and will be worse in developing countries. Without a consensus for preventive action, families and communities will be disproportionately affected. In the long run, inequalities in health, physical and...
Notícias
Data de publicação: 10/12/2021 - 13:11
Fifteen years after visiting Fiocruz as a tourist, Pietro Lazzeri returned to the Foundation on Tuesday (12/07), this time as Switzerland ambassador. In office for six months, he met with Fiocruz members at the Fiocruz Global Health Center (CRIS/Fiocruz), where he proposed to expand technical and scientific cooperation. He also visited Bio-Manguinhos, where he found out that some of the machines used in the production of the COVID-19 vaccine...
Notícias
O conteúdo deste portal pode ser utilizado para todos os fins não comerciais, respeitados e reservados os direitos morais dos autores.
